Neu­ro­crine wins ap­proval of In­grez­za 'sprin­kle' for­mu­la­tion for pa­tients with trou­ble swal­low­ing

Neu­ro­crine Bio­sciences won FDA ap­proval on Tues­day for a new for­mu­la­tion that may help In­grez­za go down in a more de­light­ful way.

The oral gran­ules are de­signed to be opened and sprin­kled over soft foods, as op­posed to the com­pa­ny’s cur­rent­ly ap­proved cap­sules that are in­tend­ed to be swal­lowed whole. In­grez­za was ap­proved in 2017 and 2023 for tar­dive dysk­i­ne­sia and Hunt­ing­ton’s chorea, re­spec­tive­ly — two con­di­tions that may im­pact pa­tients’ abil­i­ty to swal­low. Neu­ro­crine com­mer­cial chief Er­ic Benevich said on the com­pa­ny’s fourth-quar­ter 2023 earn­ings call in Feb­ru­ary that an es­ti­mat­ed 5% to 10% of these pa­tients have dif­fi­cul­ty swal­low­ing, ac­cord­ing to an Al­phaSense tran­script.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER